伊布利特致心律失常及安全性评价

陈超峰; 楚建民; 王靖; 郝素芳

doi:10.13201/j.issn.1001-1439.2017.11.022

伊布利特致心律失常及安全性评价

- 1 江苏省徐州市第三人民医院心内科(江苏徐州, 221005);
- 2 中国医学科学院阜外医院56病区(北京, 100037)

详细信息

通讯作者: 楚建民, E-mail:51362892@qq.com

中图分类号: R541.7

收稿日期: 2017-07-14

Ibutilide-induced arrhythmias:safety evaluation

- 1 Department of Cardiology, the Third People's Hospital of Xuzhou, Xuzhou, Jiangsu 221005 China;
- 2 Department of 56, Chinese Academy of Medical Sciences Fuwai Hospital, Beijing 100037, China

More Information

Corresponding author: CHU Jianmin, E-mail: 51362892@qq.com

Received Date: 14 July 2017

摘要

摘要: 目的:探讨静脉应用伊布利特的安全性。方法:结合2例心房颤动射频消融术后患者于静脉推注伊布利特后出现的心律失常并复习相关文献。结果:伊布利特的最严重不良反应为多形性室性心动过速, 尖端扭转性室性心动过速 (TdP) 为表现之一, 发生率为1%~8%, TdP一般发生于用药40min内。其防治措施如下:用药前电解质异常患者应纠正电解质;用药期间进行心电监测;女性患者较男性更易出现心律失常, 应予以注意;一旦出现TdP应立即停药, 给予电复律, 同时给予药物异丙基肾上腺素、阿托品、钾镁及β受体阻滞剂。结论:伊布利特引起心室肌复极异常与早期后除极致触发活动有关。
- 心律失常 /
- 伊布利特 /
- 不良反应 /
- 安全性评价
Abstract: Objective:To observe the safety of intravenous Ibutilide.Method:Two patients who underwent radiofrequency catheter ablation and given intravenous administration of Ibutilide were studied.Related documents were reviewed.Result:Ibutilide exhibited the most severe for polymorphic ventricular tachycardia, torsade de pointes (TdP) ventricular tachycardia as one manifestation of heart beat, and the incidence rate was about 1%~8%.The time to TdP onset was within 40 minutes after drug administration.The measures of prevention and treatment of ibutilide-induced arrhythmias were as follows:electolyle abnormalities should be corrected before treatment start;ECG monitoring should be carried out during ibutilide treatment;Ibutilide-induced arrhymics was liable to occure in women than men, and caution is needed when using ibutilide in women.If arrhythemias occured, the drug should be withdrawn immediately.Electrical cardiversion, isoprenaline and atropin injections, potassium and magnesium supplements as well as beta blockers should be given.Conclusion:The mechanism of ibutilide-induced TdP may be related to the vertricular repolarization abnormalities and triggered activity after early defibrillation.
- arrhythmia /
- Ibutilide /
- aderse reactions /
- safety evaluation

HTML全文

参考文献(17)

[1]	楚建民, 张澍.抗心律失常新药-Ibutilide[J].中华心律失常学杂志, 2002, 6 (1):60-62.
[2]	FUSTER V, RYDEN L E, CANNOM D S, et al.2011 ACC/AHA/HRS focused updates incorporated into the ACC/AHA/ESC 2006 Guidelines for the management of patients with atrial fibrillation[J].J Am Coll Cardiol, 2011, 57:101-101.
[3]	刘美, 褚松筠, 王新刚.伊布利特转复心房颤动致尖端扭转型室性心动过速1例[J].中华老年多器官疾病杂志, 2013, 12 (6):462-463.
[4]	秦静, 宋菲, 马莉, 等.国产伊布利特治疗心房颤动和扑动的有效性及安全性系统评价[J].中国循证医学杂志, 2012, 12 (7):770-776.
[5]	梁岩, 高鑫, 朱俊.Ibutilide转复心房颤动的Meta分析[J].中国心脏起搏与电生理杂志, 2001, 15 (6):394-398.
[6]	GOWDA R M, KHAN I A, PUNUKOLLU G, et al.Female preponderance in ibutilide-induced torsade de pointes[J].Int J Cardiol, 2004, 95:219-222.
[7]	CHILADAKIS J A, KALOGEROPOULOS A, PATSOURAS N, et al.Ibutilide added to propafenone for the conversion of atrial fibrillation and atrial flutter[J].J Am Coll Cardiol, 2004, 44:859-863.
[8]	HONGO R H, THEMISTOCLAKIS S, RAVIELE A, et al.Use of ibutilide in cardioversion of patients with atrial fibrillation or atrial flutter treated with class IC agents[J].J Am Coll Cardiol, 2004, 44:864-868.
[9]	EIDHER U, FREIHOFF F, KALTENBRUNNER W, et al.Efficacy and safety of ibutilide for the conversion fo monomorphic atrial tachycardia[J].Pacing Clin Electrophysiol, 2006, 29:358-362.
[10]	KAFKAS N V, PATSILINAKOS S P, MERTZANOS G A, et al.Conversion efficacy of intravenous ibutilide compared with intravenous amiodarone in patients with recent-onset atrial fibrillation and atrial flutter[J].Int J Cardiol, 2007, 118:321-325.
[11]	HOYER A W, BALAJI S.The safety and efficacy of ibutilide in children and in patients with congenital heart disease[J].Pacing Clin Electrophysiol, 2007, 30:1003-10008.
[12]	蒋桔泉, 丁世芳, 陈志楠, 等.12例尖端扭转性室性心动过速临床分析[J].临床心血管病杂志, 2011, 27 (3):180-181.
[13]	高永红, 张存泰, 阮磊, 等.伊布利特致尖端扭转性室性心动过速机制的研究[J].临床心血管病杂志, 2010, 26 (5):378-381.
[14]	向小峰, 唐其柱, 胡佑伦.心肌M细胞及其在长QT综合征电生理机制中的研究进展[J].中国心脏起搏与心电生理杂志, 2002, 16 (1):64-66.
[15]	阮燕菲, 刘念, 周强, 等.尖端扭转型室性心动过速性别差异的机制研究[J].中华心血管病杂志, 2003, 31 (7):502-502.
[16]	LU H R, REMEYSEN P, SOMERS K, et al.Female gender is a risk factor for drug-induced long QT and cardiac arrhythman in vivo rabbit model[J].J Cardiovasc Electrophysiol, 2001, 12:538-545.
[17]	田蕾, 蒋娟娟, 黄一玲, 等.伊布利特注射液的中国人人体药动学[J].中国新药与临床杂志, 2006, 25 (7):531-534.